Free Trial
NASDAQ:AUPH

Aurinia Pharmaceuticals (AUPH) Stock Price, News & Analysis

Aurinia Pharmaceuticals logo
$11.43 -0.18 (-1.55%)
Closing price 08/7/2025 04:00 PM Eastern
Extended Trading
$11.44 +0.02 (+0.13%)
As of 08/7/2025 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Aurinia Pharmaceuticals Stock (NASDAQ:AUPH)

Key Stats

Today's Range
$11.32
$11.67
50-Day Range
$7.47
$11.70
52-Week Range
$5.29
$11.80
Volume
2.86 million shs
Average Volume
2.67 million shs
Market Capitalization
$1.50 billion
P/E Ratio
26.58
Dividend Yield
N/A
Price Target
$12.00
Consensus Rating
Buy

Company Overview

Aurinia Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
43rd Percentile Overall Score

AUPH MarketRank™: 

Aurinia Pharmaceuticals scored higher than 43% of companies evaluated by MarketBeat, and ranked 634th out of 921 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Aurinia Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Aurinia Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.

  • Read more about Aurinia Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Aurinia Pharmaceuticals are expected to grow by 409.09% in the coming year, from $0.11 to $0.56 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Aurinia Pharmaceuticals is 26.58, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 27.80.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Aurinia Pharmaceuticals is 26.58, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 29.88.

  • Price to Book Value per Share Ratio

    Aurinia Pharmaceuticals has a P/B Ratio of 4.48. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    8.91% of the float of Aurinia Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Aurinia Pharmaceuticals has a short interest ratio ("days to cover") of 7.
  • Change versus previous month

    Short interest in Aurinia Pharmaceuticals has recently increased by 6.09%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Aurinia Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Aurinia Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    8.91% of the float of Aurinia Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Aurinia Pharmaceuticals has a short interest ratio ("days to cover") of 7.
  • Change versus previous month

    Short interest in Aurinia Pharmaceuticals has recently increased by 6.09%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Aurinia Pharmaceuticals has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.39 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 40 news articles for Aurinia Pharmaceuticals this week, compared to 4 articles on an average week.
  • Search Interest

    Only 28 people have searched for AUPH on MarketBeat in the last 30 days. This is a decrease of -3% compared to the previous 30 days.
  • MarketBeat Follows

    Only 2 people have added Aurinia Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Aurinia Pharmaceuticals insiders have bought more of their company's stock than they have sold. Specifically, they have bought $13,590,000.00 in company stock and sold $0.00 in company stock.

  • Percentage Held by Insiders

    12.20% of the stock of Aurinia Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 36.83% of the stock of Aurinia Pharmaceuticals is held by institutions.

  • Read more about Aurinia Pharmaceuticals' insider trading history.
Receive AUPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aurinia Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

AUPH Stock News Headlines

HIDDEN IN THE BOOK OF GENESIS…
“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 trillion vault of untapped American wealth. Former CIA advisor Jim Rickards calls it the “Old Testament Wealth Code” — and says it could transform your financial future. He’s revealing everything in a new presentation.
See More Headlines

AUPH Stock Analysis - Frequently Asked Questions

Aurinia Pharmaceuticals' stock was trading at $8.98 at the beginning of the year. Since then, AUPH stock has increased by 27.3% and is now trading at $11.43.

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) posted its earnings results on Thursday, July, 31st. The biotechnology company reported $0.16 EPS for the quarter, missing analysts' consensus estimates of $0.17 by $0.01. The biotechnology company had revenue of $70.01 million for the quarter, compared to analysts' expectations of $64.27 million. Aurinia Pharmaceuticals had a net margin of 23.31% and a trailing twelve-month return on equity of 20.06%.
Read the conference call transcript
.

Top institutional shareholders of Aurinia Pharmaceuticals include Connor Clark & Lunn Investment Management Ltd. (0.49%), Hussman Strategic Advisors Inc. (0.27%), Nordea Investment Management AB (0.26%) and IFP Advisors Inc (0.19%). Insiders that own company stock include Kevin Tang, Peter Greenleaf, Matthew Maxwell Donley, Joseph M Miller, Scott Michael Habig, Stephen P Robertson, Greg Keenan, David RW Jayne, Jeffrey Allen Bailey and Joseph P Hagan.
View institutional ownership trends
.

Shares of AUPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Aurinia Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), Netflix (NFLX), JPMorgan Chase & Co. (JPM) and Intel (INTC).

Company Calendar

Last Earnings
7/31/2025
Today
8/07/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - DRUGS
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:AUPH
CIK
1600620
Employees
300
Year Founded
N/A

Price Target and Rating

High Price Target
$17.00
Low Price Target
$9.00
Potential Upside/Downside
+5.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

EPS (Trailing Twelve Months)
$0.43
Trailing P/E Ratio
26.58
Forward P/E Ratio
103.91
P/E Growth
N/A
Net Income
$5.75 million
Net Margins
23.31%
Pretax Margin
24.02%
Return on Equity
20.06%
Return on Assets
13.81%

Debt

Debt-to-Equity Ratio
0.18
Current Ratio
5.23
Quick Ratio
4.63

Sales & Book Value

Annual Sales
$235.13 million
Price / Sales
6.40
Cash Flow
$0.30 per share
Price / Cash Flow
37.94
Book Value
$2.55 per share
Price / Book
4.48

Miscellaneous

Outstanding Shares
131,630,000
Free Float
115,571,000
Market Cap
$1.50 billion
Optionable
Optionable
Beta
1.23

Social Links

Analysts Agree—These Gold Picks Outshine the Rest Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

This page (NASDAQ:AUPH) was last updated on 8/8/2025 by MarketBeat.com Staff
From Our Partners